Company intelligence / Profile preview
RxMP Therapeutics
Miami, Florida, United Statesrxmpt.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
RxMP Therapeutics is developing RMP-HPEs, a novel class of systemically delivered hemostatic agents derived from red blood cells. Their lead candidate, RMP‑402, is in preclinical development and has shown promise in enhancing coagulation without increasing the risk of off-target thrombosis. The company recently entered a Cooperative Research and Development Agreement with the U.S. Department of Defense's Institute of Surgical Research to validate efficacy in large animal models.
- Therapeutic areas
- NeurologyHematology
- Modalities
- BiologicBlood and blood products (Red cell-derived microparticles)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
U.S. Department of Defense Institute of Surgical Research (CRADA for preclinical validation)
Beyond the preview
Go deeper on RxMP Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RxMP Therapeutics.